BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 35320687)

  • 21. Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic.
    Sasso JM; Tenchov R; Wang D; Johnson LS; Wang X; Zhou QA
    Biochemistry; 2023 Feb; 62(3):601-623. PubMed ID: 35856839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
    Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
    Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Haven't got a glue: Protein surface variation for the design of molecular glue degraders.
    Kozicka Z; Thomä NH
    Cell Chem Biol; 2021 Jul; 28(7):1032-1047. PubMed ID: 33930325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Translation of Targeted Protein Degraders.
    Kong NR; Jones LH
    Clin Pharmacol Ther; 2023 Sep; 114(3):558-568. PubMed ID: 37399310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crbn-based molecular Glues: Breakthroughs and perspectives.
    An J; Zhang X
    Bioorg Med Chem; 2024 Apr; 104():117683. PubMed ID: 38552596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation.
    Riching KM; Caine EA; Urh M; Daniels DL
    Chem Soc Rev; 2022 Jul; 51(14):6210-6221. PubMed ID: 35792307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted protein degradation and the enzymology of degraders.
    Fisher SL; Phillips AJ
    Curr Opin Chem Biol; 2018 Jun; 44():47-55. PubMed ID: 29885948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Frontiers in the Discovery and Development of PROTACs.
    Barghout SH
    Anticancer Agents Med Chem; 2022 Aug; 22(15):2656-2661. PubMed ID: 35418290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanistic and Structural Features of PROTAC Ternary Complexes.
    Casement R; Bond A; Craigon C; Ciulli A
    Methods Mol Biol; 2021; 2365():79-113. PubMed ID: 34432240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HECT-Type E3 Ubiquitin Ligases in Cancer.
    Bernassola F; Chillemi G; Melino G
    Trends Biochem Sci; 2019 Dec; 44(12):1057-1075. PubMed ID: 31610939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identifying E3 Ligase Substrates With Quantitative Degradation Proteomics.
    Jordan VN; Ordureau A; An H
    Chembiochem; 2023 Aug; 24(16):e202300108. PubMed ID: 37166757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Receptor Elimination by E3 Ubiquitin Ligase Recruitment (REULR): A Targeted Protein Degradation Toolbox.
    Siepe DH; Picton LK; Garcia KC
    ACS Synth Biol; 2023 Apr; 12(4):1081-1093. PubMed ID: 37011906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An E3 ligase guide to the galaxy of small-molecule-induced protein degradation.
    Jevtić P; Haakonsen DL; Rapé M
    Cell Chem Biol; 2021 Jul; 28(7):1000-1013. PubMed ID: 33891901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High throughput E3 ligase degron binding assays for novel PROTAC ligand discovery.
    Guenette RG; Potts PR
    Methods Enzymol; 2023; 681():23-39. PubMed ID: 36764759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic approaches to identify E3 ligase substrates.
    Iconomou M; Saunders DN
    Biochem J; 2016 Nov; 473(22):4083-4101. PubMed ID: 27834739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted protein degradation: Emerging concepts and protein state-specific targeting principles.
    Tao AJ; Gadbois GE; Buczynski SA; Ferguson FM
    Curr Opin Chem Biol; 2022 Apr; 67():102114. PubMed ID: 35042023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perspectives on the development of first-in-class protein degraders.
    Rambacher KM; Calabrese MF; Yamaguchi M
    Future Med Chem; 2021 Jul; 13(14):1203-1226. PubMed ID: 34015962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring the Rampant Expansion of Ubiquitin Proteomics.
    Rose A; Mayor T
    Methods Mol Biol; 2018; 1844():345-362. PubMed ID: 30242720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mathematical Model for Covalent Proteolysis Targeting Chimeras: Thermodynamics and Kinetics Underlying Catalytic Efficiency.
    Chaudhry C
    J Med Chem; 2023 May; 66(9):6239-6250. PubMed ID: 37102218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.